Cannabis rescheduling to Schedule III is expected, allowing business expense deductions and medical recognition. This improves profitability and legal standing for U.S. cannabis companies, driving ETF appreciation. MSOS rallied 25% on news and may continue upward as rescheduling finalizes. Rescheduling delay or failure; structural industry headwinds remain.
MSOS
HIGH
Apr 22, 17:10
Key Points
['Tax burden reduction significant', 'Federal medical benefits recognition', 'ETF captures broad sector rally', 'News-driven volatility high', 'Policy execution uncertain']
April 22, 2026 at 17:10